GlassScriptPhysician profile
Charles G Herbst
NPI 1437145737
$32,198.90
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $3,633 · 2021: $357.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $30,180.94 | 2019-2021 | |
| Janssen Biotech, INC. | $834.50 | 2019-2021 | |
| Amgen INC. | $318.65 | 2019-2021 | |
| Pfizer INC. | $248.64 | 2019-2021 | |
| Glaxosmithkline, LLC. | $159.88 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $141.71 | 2019-2021 | |
| Ucb, INC. | $101.86 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $52.27 | 2019-2021 | |
| Celgene Corporation | $43.67 | 2019 | |
| Radius Health, INC. | $32.27 | 2019 | |
| Lilly USA, LLC | $31.25 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.48 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.57 | 2019 | |
| Horizon Therapeutics Plc | $16.21 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Herbst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.